|
Factor V Leiden and Venous Thrombosis Case Study Answers and Bibliography Answer 1 The prevalence of FVL was 22.6% in cases and 3.6% in controls. While 3.2% of cases were homozygous for FVL, there were no homozygotes among controls. (The expected number among controls is 0.05 based on Hardy-Weinberg equilibrium,* corresponding to prevalence of 3.2x10-4 , or 1 in 3117.) Prevalence estimates for both groups are similar to those from previous studies—some of which were based on the same study population. *p2=163/169=0.964497, p=0.9820881, q=0.0179118, 2pq=0.0351821, q2=3.2x10-4 Answer 2 Odds ratios of 5.0, 3.7, and
3.8 obtained in this study are essentially the same, given
wide confidence intervals. However, two
additional points should be considered: 1.
Data for FVL heterozygotes and homozygotes were combined in
this analysis. No odds ratio could be calculated for
homozygotes because there were only five among cases and
none among controls. FVL homozygotes could be at
higher risk of DVT than heterozygotes 2. Clearly, both OC use and FVL are risk factors for DVT. When deciding whether to prescribe OCs, clinicians are more concerned with absolute risk than with relative risk. Answer 3 In these data, 1.
Rge¹
Rg + Re – 1, because 30 > 7 + 4 - 1, but 2.
Rge»
Rg x Re, because 30»
7 x 4 These findings indicate that there is more than additive interaction; the effects of these factors are approximately multiplicative. From a clinical standpoint, the relevant finding shows that women with FVL who use OCs are at much higher risk for venous thrombosis than are other OC users. Answer 4 The case-only analysis yields
OR case-only»
1, suggesting that no interaction
exists between FVL and OC use in venous thrombosis under a
multiplicative model. Additive or other models of
interaction are not excluded by this result. One way to
check that genotype and environmental exposure are
independent is to compute ORcontrol-only=0.79 in this study. The case-only design does not yield estimates of the effect of genotype or environmental exposures, or their joint effects. Answer 5 Although the authors refer to
this as a population-based study, only the cases can really
be considered population-based. The controls were
recruited among friends and acquaintances of cases (60%), or
partners of other patients at the anticoagulation
clinics. Friends may share the same method of birth
control, which would tend to inflate the estimated
person-years at risk in OC users and thus diminish the
estimated absolute risk in this group. (However, the authors
noted that prevalence of OC use in this study was similar to
that in local population surveys.) Current OC use was defined as
use within 30 days before thrombosis (or index date in
controls). Apportioning person-years at risk based on
current exposure among controls assumes that OC use patterns
were unchanged throughout the course of the study. Subsequent studies have shown that risk of venous thrombosis
is greatest during the first year of OC use. Therefore, relevant information for assessing the effect of
OC exposures should ideally include dates of initiation and duration of use. Cases and controls were matched by age, which is critical, because the risk of venous thrombosis increases dramatically with age. However, the analysis was done in unmatched fashion. Answer 6
Without FVL: 3.0 – 0.8 = 2.2
With FVL: 28.5 – 5.7 = 22.8 The joint effect of the two factors is more than additive. Answer 7 Excess
deaths associated with OC use in women with FVL: (0.57 –
0.11) / 10,000 = 0.46 death / 10,000 py Number
of women with FVL denied OCs: 10,000 py / 0.46 deaths =
21,739 py / 1 death Number
needed to screen to find 20,000 with FVL: 20,000 / 0.05
prevalence of FVL »
400,000
NNS = NNT/prevalence = (1/risk difference)/prevalence =
1/4.6x10-5/0.05» 400,000 NOTE: Nonuse of OCs by 20,000 women for 1 year is in theory equivalent to nonuse by 10,000 women for 2 years; however, the risk for thrombosis appears to be highest in the first year. Answer 8
Bibliography Seligsohn U, Lubetsky A. Genetic
susceptibility to venous thrombosis. New Engl J Med 2001;344:1222-1231. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in OC users who are carriers of factor V Leiden mutation. Lancet 1994;344:1453-157. |
|
last updated August 09, 2004